Pleural Mesothelioma (PM) is a rare type of cancer affecting the mesothelial cells of the lungs. 80% of the patients have been exposed to asbestos before being diagnosed, but only 5% of the people exposed to asbestos develop mesothelioma. Through a literature study and community workshop, several pathways have been identified to contribute to the development of the disease, which are captured in this PM pathway. Frequently mutated genes are highlighted in bold, where red nodes indicate tumor suppressor genes, and yellow indicates oncogenes. This pathway has been published in Frontiers in Oncology: https://doi.org/10.3389/fonc.2022.849640 Mesothelioma d4e a11 Cytochrome C f72 fa1 aa0 ac8 fa1 Also known as Krebs or citric acid cycle dcf P21 f4a f4a b0d The Cancer Genome Atlas Data Portal entry for BAP1: https://portal.gdc.cancer.gov/genes/ENSG00000163930 Onco KnowledgeBase entry for BAP1: https://www.oncokb.org/gene/BAP1 neXtProt entry for BAP1: https://www.nextprot.org/entry/NX_Q92560/ f4a df0 acb fe3 b0d bfe bfe ec6 fa1 aa0 fa1 fa1 Homology Mapping from Mus musculus to Homo sapiens: Original ID = L:21687 NDR1/2 NDR1/2 f72 f72 f72 Cytochrome C parentid=P35222; parentsymbol=CTNNB1; site=yLDsGIHsGATtTAP; position=ser37; sitegrpid=447582; ptm=p; direction=d parentid=P35222; parentsymbol=CTNNB1; site=QQQsyLDsGIHsGAT; position=ser33; sitegrpid=447487; ptm=p; direction=d parentid=P35222; parentsymbol=CTNNB1; site=GIHsGATtTAPsLsG; position=thr41; sitegrpid=447583; ptm=p; direction=d parentid=P35222; parentsymbol=CTNNB1; site=yLDsGIHsGATtTAP; position=ser37; sitegrpid=447582; ptm=p; direction=d parentid=P35222; parentsymbol=CTNNB1; site=GIHsGATtTAPsLsG; position=thr41; sitegrpid=447583; ptm=p; direction=d parentid=P35222; parentsymbol=CTNNB1; site=QQQsyLDsGIHsGAT; position=ser33; sitegrpid=447487; ptm=p; direction=d b7f f3b bc2 bf7 fa1 b7f ebb b52 Stabilisation of ITPR3 through deubiquitination f4a dda a11 bc2 b7f f3b ba4 ba4 bc2 df0 a11 ba4 bbe b7f ebb bc2 ebb bf7 b7f ebb bf7 b7f bc2 f77 a9c bf7 bf7 b7f fa1 fa1 fa1 a2f dda ba4 b52 ebb bf7 bf7 f3f bf7 bf7 bbe fa1 b7f b7f ba4 fa1 e58 bf7 b7f b7f b7f ebb ba4 a0a b7f ebb b7f bf7 b7f a11 e9e f52 f5d f05 f05 f5d f5d b52 df0 f5d f90 ad4 f90 df0 f05 f90 f05 df0 f05 f05 df0 f52 f05 df0 b52 f90 df0 f52 df0 f52 df0 df0 f4a f05 f5d f90 f52 df0 d1e f52 df0 f05 df0 f52 f90 f52 df0 df0 fd1 f5d df0 ca4 bf7 f05 df0 bc2 f52 b52 f52 f90 f52 f52 fd1 df0 f5d df0 b52 f90 df0 b52 fa1 b7f b7f b7f fa1 e58 b52 b52 bf7 bf7 bf7 bf7 bf7 bf7 bf7 bf7 ca4 ca4 ca4 ca4 ba4 bc2 bc2 bc2 bc2 bc2 Voltage-dependent anion channel b52 b83 b0d aa0 fa1 fa1 aa0 e58 a2f b52 fa1 fa1 fa1 fa1 27300434 PubMed YAP/TAZ at the Roots of Cancer. Cancer Cell 2016 Zanconato F Cordenonsi M Piccolo S 21484256 PubMed An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys 2011 Eletr ZM Wilkinson KD 34073720 PubMed Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Cancers (Basel) 2021 Napoli F Listì A Zambelli V Witel G Bironzo P Papotti M Volante M Scagliotti G Righi L 10.2174/9781681081946116010017 DOI Biomolecular Pathways and Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma: Present Status and Future Directions 2015 Marie-Claude Jaurand Didier Jean 31283845 PubMed Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 2019 Carbone M Adusumilli PS Alexander HR Jr Baas P Bardelli F Bononi A Bueno R Felley-Bosco E Galateau-Salle F Jablons D Mansfield AS Minaai M de Perrot M Pesavento P Rusch V Severson DT Taioli E Tsao A Woodard G Yang H Zauderer MG Pass HI 33329574 PubMed TERT-Regulation and Roles in Cancer Formation. Front Immunol 2020 Dratwa M Wysoczańska B Łacina P Kubik T Bogunia-Kubik K malignant pleural mesothelioma DOID:7474 Human Disease Ontology disease pathway PW:0000013 Pathway Ontology 28740119 PubMed Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 2017 Yap TA Aerts JG Popat S Fennell DA 16216411 PubMed Molecular pathways in malignant pleural mesothelioma. Cancer Lett 2006 Whitson BA Kratzke RA 33800494 PubMed Identification of Overexpressed Genes in Malignant Pleural Mesothelioma. Int J Mol Sci 2021 Morani F Bisceglia L Rosini G Mutti L Melaiu O Landi S Gemignani F 31867277 PubMed The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Front Oncol 2019 Chu GJ van Zandwijk N Rasko JEJ 23975423 PubMed Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014 Tallet A Nault JC Renier A Hysi I Galateau-Sallé F Cazes A Copin MC Hofman P Andujar P Le Pimpec-Barthes F Zucman-Rossi J Jaurand MC Jean D 28614305 PubMed BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature 2017 Bononi A Giorgi C Patergnani S Larson D Verbruggen K Tanji M Pellegrini L Signorato V Olivetto F Pastorino S Nasu M Napolitano A Gaudino G Morris P Sakamoto G Ferris LK Danese A Raimondi A Tacchetti C Kuchay S Pass HI Affar EB Yang H Pinton P Carbone M 24607545 PubMed RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett 2014 Volodko N Gordon M Salla M Ghazaleh HA Baksh S 12771921 PubMed Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 2003 Edwards JG McLaren J Jones JL Waller DA O'Byrne KJ 24780002 PubMed The ins and outs of fibroblast growth factor receptor signalling. Clin Sci (Lond) 2014 Coleman SJ Bruce C Chioni AM Kocher HM Grose RP 29565815 PubMed Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma. Cancers (Basel) 2018 Sekido Y mesothelial cell of pleura CL:1000491 Cell Ontology 15686623 PubMed Wnt signaling in disease and in development. Cell Res 2005 Nusse R 30073421 PubMed The hippo pathway provides novel insights into lung cancer and mesothelioma treatment. J Cancer Res Clin Oncol 2018 Liu XL Zuo R Ou WB 33462414 PubMed Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ 2021 Masclef L Ahmed O Estavoyer B Larrivée B Labrecque N Nijnik A Affar EB 12589646 PubMed The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions. Cancer 2003 Illei PB Ladanyi M Rusch VW Zakowski MF 12612292 PubMed Regulation of matrix metalloprotease activity in malignant mesothelioma cell lines by growth factors. Thorax 2003 Liu Z Klominek J 23550303 PubMed BAP1 and cancer. Nat Rev Cancer 2013 Carbone M Yang H Pass HI Krausz T Testa JR Gaudino G 32317288 PubMed Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup. Clin Cancer Res 2020 Pirker C Bilecz A Grusch M Mohr T Heidenreich B Laszlo V Stockhammer P Lötsch-Gojo D Gojo J Gabler L Spiegl-Kreinecker S Dome B Steindl A Klikovits T Hoda MA Jakopovic M Samarzija M Mohorcic K Kern I Kiesel B Brcic L Oberndorfer F Müllauer L Klepetko W Schmidt WM Kumar R Hegedus B Berger W 32882916 PubMed Genomics and Functional Genomics of Malignant Pleural Mesothelioma. Int J Mol Sci 2020 Cakiroglu E Senturk S 27507853 PubMed Genomic Landscape of Malignant Mesotheliomas. Mol Cancer Ther 2016 Kato S Tomson BN Buys TP Elkin SK Carter JL Kurzrock R 30101371 PubMed Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms. Clin Transl Med 2018 Dobrokhotov O Samsonov M Sokabe M Hirata H 19753302 PubMed Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One 2009 Crispi S Calogero RA Santini M Mellone P Vincenzi B Citro G Vicidomini G Fasano S Meccariello R Cobellis G Menegozzo S Pierantoni R Facciolo F Baldi A Menegozzo M 26078352 PubMed Reactive oxygen species a double-edged sword for mesothelioma. Oncotarget 2015 Benedetti S Nuvoli B Catalani S Galati R altered autophagy pathway PW:0001562 Pathway Ontology 29371938 PubMed Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma. Oncotarget 2017 Hylebos M Van Camp G Vandeweyer G Fransen E Beyens M Cornelissen R Suls A Pauwels P van Meerbeeck JP Op de Beeck K 32768523 PubMed TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends. Cancer Lett 2020 Yuan X Dai M Xu D 30642555 PubMed Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2019 Chapel DB Churg A Santoni-Rugiu E Tsujimura T Hiroshima K Husain AN 31285550 PubMed Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene 2019 Yuan X Larsson C Xu D 28327630 PubMed Rassf Proteins as Modulators of Mst1 Kinase Activity. Sci Rep 2017 Bitra A Sistla S Mariam J Malvi H Anand R 33232793 PubMed Fundamental insights into the interaction between telomerase/TERT and intracellular signaling pathways. Biochimie 2021 Ghareghomi S Ahmadian S Zarghami N Kahroba H 27282309 PubMed The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing. J Thorac Oncol 2016 Hylebos M Van Camp G van Meerbeeck JP Op de Beeck K 26358421 PubMed Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment. Crit Rev Oncol Hematol 2016 Urso L Calabrese F Favaretto A Conte P Pasello G mesothelial cell CL:0000077 Cell Ontology 23395095 PubMed New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 2013 Mossman BT Shukla A Heintz NH Verschraegen CF Thomas A Hassan R 9378538 PubMed Differential motile response of human malignant mesothelioma cells to fibronectin, laminin and collagen type IV: the role of beta1 integrins. Int J Cancer 1997 Klominek J Sumitran Karuppan S Hauzenberger D 34226685 PubMed Biological basis for novel mesothelioma therapies. Br J Cancer 2021 Obacz J Yung H Shamseddin M Linnane E Liu X Azad AA Rassl DM Fairen-Jimenez D Rintoul RC Nikolić MZ Marciniak SJ